It encompasses cortisol binding to the mineralocorticoid receptors with consequent sodium retention and hypervolemia, increased production of endothelin-1 and other vasoconstrictors coupled with inhibition of vasodilator release, but also a modulation of the renin–angiotensin–aldosterone system (RAAS) activity [42–45]. This evidence concerns the gene NR3C2 and Hypervolemia.